Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

16 Apr 2019

Abstract excerpt

Glioblastoma (GB) is the most common and aggressive malignant tumor of the central nervous system. Despite current intensive treatment regimens, consisting of surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ) chemotherapy, the prognosis of patients with GB remains extremely poor. Considering that alterations of the p53 tumor suppressor pathway have a key role in both GB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Glioma Diagnosis and Treatment
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31081046
DOI: 10.3892/ijo.2019.4788

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomidePMID 31081046Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read ↗

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.Semantic proximity Read ↗

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Semantic proximity Read ↗

Problems of glioblastoma multiforme drug resistanceSemantic proximity Read ↗

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.Semantic proximity Read ↗

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivoSemantic proximity Read ↗

Temozolomide and Other Alkylating Agents in Glioblastoma TherapySemantic proximity Read ↗

Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiationSemantic proximity Read ↗

Novel chemotherapeutic agents for the treatment of glioblastoma multiformeSemantic proximity Read ↗

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.Semantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.